Drug intelligence / Profile preview

nicotine + mecamylamine

Development stage: Unknown
Modality: Small Molecules
Administration: Transdermal, Oral

Overview

A combination therapy for smoking cessation that pairs nicotine (typically delivered via a skin patch) with oral mecamylamine (a nicotine antagonist). This agonist-antagonist approach works by having mecamylamine block the rewarding effects of nicotine while nicotine replacement helps manage withdrawal symptoms. Clinical studies have shown this combination to be more effective than either component alone, with significantly higher abstinence rates both short-term and long-term.

Other names: Combined Pharmacologic/Behavioral Treatment for Smoking Cessation

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on nicotine + mecamylamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nicotine + mecamylamine.

Explore the full profile